Literature DB >> 16600214

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Aaron N Nguyen1, Elizabeth G Stebbins, Margaret Henson, Gilbert O'Young, Sun J Choi, Diana Quon, Debby Damm, Mamatha Reddy, Jing Y Ma, Edwin Haghnazari, Ann M Kapoun, Satyanarayana Medicherla, Andy Protter, George F Schreiner, Noriyoshi Kurihara, Judy Anderson, G David Roodman, Tony A Navas, Linda S Higgins.   

Abstract

The multiple myeloma (MM) bone marrow (BM) microenvironment plays a critical role in supporting tumor growth and survival as well as in promoting formation of osteolytic lesions. Recent results suggest that the p38 mitogen-activated protein kinase (MAPK) is an important factor in maintaining this activated environment. In this report, we demonstrate that the p38alpha MAPK inhibitor, SCIO-469, suppresses secretion of the tumor-supportive factors IL-6 and VEGF from BM stromal cells (BMSCs) as well as cocultures of BMSCs with MM cells, resulting in reduction in MM cell proliferation. Additionally, we show that SCIO-469 prevents TNFalpha-induced adhesion of MM cells to BMSCs through an ICAM-1- and VCAM-1-independent mechanism. Microarray analysis revealed a novel set of TNFalpha-induced chemokines in BMSCs that is strongly inhibited by SCIO-469. Furthermore, reintroduction of chemokines CXCL10 and CCL8 to BMSCs overcomes the inhibitory effect of SCIO-469 on TNFalpha-induced MM adhesion. Lastly, we show that SCIO-469 inhibits secretion and expression of the osteoclast-activating factors IL-11, RANKL, and MIP-1alpha as well as prevents human osteoclast formation in vitro. Collectively, these results suggest that SCIO-469 treatment can suppress factors in the bone marrow microenvironment to inhibit MM cell proliferation and adhesion and also to alleviate osteolytic activation in MM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600214     DOI: 10.1016/j.yexcr.2006.02.026

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  17 in total

1.  CYR61/CCN1 overexpression in the myeloma microenvironment is associated with superior survival and reduced bone disease.

Authors:  Sarah K Johnson; James P Stewart; Rakesh Bam; Pingping Qu; Bart Barlogie; Frits van Rhee; John D Shaughnessy; Joshua Epstein; Shmuel Yaccoby
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

2.  Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.

Authors:  Chunming Gu; Tianfu Li; Zhao Yin; Shengting Chen; Jia Fei; Jianping Shen; Yuan Zhang
Journal:  Funct Integr Genomics       Date:  2016-09-19       Impact factor: 3.410

3.  Tumor cell p38 MAPK: A trigger of cancer bone osteolysis.

Authors:  Huan Liu; Jin He; Jing Yang
Journal:  Cancer Cell Microenviron       Date:  2015-01-01

4.  p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.

Authors:  Jin He; Zhiqiang Liu; Yuhuan Zheng; Jianfei Qian; Haiyan Li; Yong Lu; Jingda Xu; Bangxing Hong; Mingjun Zhang; Pei Lin; Zhen Cai; Robert Z Orlowski; Larry W Kwak; Qing Yi; Jing Yang
Journal:  Cancer Res       Date:  2012-10-11       Impact factor: 12.701

5.  Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation.

Authors:  Yuko Hiruma; Tadashi Honjo; Diane F Jelinek; Jolene J Windle; Jaekyoon Shin; G David Roodman; Noriyoshi Kurihara
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

Review 6.  Recent advances in antimultiple myeloma drug development.

Authors:  Nuozhou Wang; Patrick Bartlow; Qin Ouyang; Xiang-Qun Xie
Journal:  Pharm Pat Anal       Date:  2014-05

7.  A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.

Authors:  Yuko Hiruma; Noriyoshi Kurihara; Mark A Subler; Hua Zhou; Christina S Boykin; Heju Zhang; Seiichi Ishizuka; David W Dempster; G David Roodman; Jolene J Windle
Journal:  Hum Mol Genet       Date:  2008-09-02       Impact factor: 6.150

8.  Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.

Authors:  Leander Gaul; Sonja Mandl-Weber; Philipp Baumann; Bertold Emmerich; Ralf Schmidmaier
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-25       Impact factor: 4.553

9.  p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.

Authors:  Satyanarayana Medicherla; Scott Wadsworth; Breda Cullen; Derek Silcock; Jing Y Ma; Ruban Mangadu; Irene Kerr; Sarvajit Chakravarty; Gregory L Luedtke; Sundeep Dugar; Andrew A Protter; Linda S Higgins
Journal:  Diabetes Metab Syndr Obes       Date:  2009-06-23       Impact factor: 3.168

10.  Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Authors:  J Yang; J He; J Wang; Y Cao; J Ling; J Qian; Y Lu; H Li; Y Zheng; Y Lan; S Hong; J Matthews; M W Starbuck; N M Navone; R Z Orlowski; P Lin; L W Kwak; Q Yi
Journal:  Leukemia       Date:  2012-03-19       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.